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Abstract: Human immunodeficiency virus (HIV) infection and acquired immune deficiency 
syndrome (AIDS) are frequently associated with neurocognitive impairment (NCI). However, 
few studies have examined the interrelationship between gender and NCI in the HIV and 
AIDS population. This cross-sectional study examined the neurocognitive (NC) functioning of 
HIV-infected male and female adults from urban Zambia. The participants included 266 HIV 
seropositive (HIV+) adults (males [n=107] and females [n=159]). Participants completed NC 
assessment by means of a comprehensive test battery using normative data from 324 HIV-
seronegative (HIV−) controls. The norms corrected for effects of age, education, and gender 
in the general population, and the test battery measures domains of attention/working memory 
(learning and delayed recall), executive function, verbal fluency, processing speed, verbal and 
visual episodic memory, and fine motor skills. An overall comparison of the HIV+ male and 
female participants yielded no statistically significant differences. Analysis of covariance results 
controlling for disease characteristics showed that HIV+ female participants had worse delayed 
recall scores than males, F(1,117) =9.70, P=0.002, partial η2=0.077. The females also evidenced 
a trend toward greater impairment on learning efficiency (P=0.015). The findings suggest that 
there are gender-related differences in NCI after controlling for disease characteristics. It was 
observed that although the HIV+ females enjoyed better health compared to their HIV+ male 
counterparts, they still had worse performance on the neuropsychological tests. This implies 
that HIV may have more NC consequences for Zambian females than males.
Keywords: HIV-1, neurocognitive functioning, gender, Zambia
Introduction
Statistics at the end of 2010 indicated that globally, 34 million people were living with 
HIV, with the worst hit region being sub-Saharan Africa.1 Reports also reflect dispari-
ties regarding rates of infection among men and women, and these too, show regional 
differences across the globe. For example, it is reported that in sub-Saharan Africa, 
nearly 60% of those infected with HIV are women, whereas in Latin America, Eastern 
Europe/Central Asia, and Asia, only 30%–35% of those affected are women.1,2
Sub-Saharan Africa, especially in its southern regions, has the world’s highest 
prevalence of HIV infection. Zambia is listed among the countries with the worst 
HIV and AIDS epidemics in this region.3 The majority of those infected with HIV in 
Zambia are females, which has led some researchers to observe that “the epidemic in 
Zambia has a female face”.4
The first AIDS diagnosis in Zambia was reported in 1984, and this was followed by a 
sharp rise in prevalence estimates.5 By 2005, it was estimated that the prevalence of HIV in 
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Zambia was twice as high in urban areas as it was in rural areas.5,6 
According to the Zambia Ministry of Health/National AIDS 
Council,7 sex disparities have been reported in the prevalence 
of HIV and AIDS, with a higher proportion of Zambian women 
(16.1%) suffering from HIV/AIDS compared to men (12.3%).
HIV-1 subtype C is of particular interest in the current 
study because it is predominant in Central, East, and Southern 
Africa, including Zambia, from which our sample is drawn. 
Furthermore, subtype C currently accounts for more than half 
of all the HIV infections worldwide, which is more than all 
the other subtypes combined.8 However, less research has 
been done on this subtype than subtype B, which dominates 
Europe and the US.
HIV is known to affect the central nervous system (CNS), 
and it has been reported that 35%–50% of infected individuals 
eventually show neurocognitive (NC) alterations.9–12 Neuro-
pathology and neuroimaging studies have documented a loss 
of neurons, especially in the frontal cortex and basal ganglia 
areas, with cerebral atrophy and demyelination of the white 
matter, particularly in patients with advanced infection and 
histories of severe immunosuppression.12,13 The associated 
cognitive changes have typically involved attention/working 
memory, speed of information processing, psychomotor 
speed, learning, delayed recall, and executive functioning.12 
Neurocognitive impairment (NCI) in HIV is also frequently 
characterized by a decline in the ability to function in every-
day activities, including the ability to perform in employment 
and other cognitively demanding tasks.14–16
There are a few studies that have examined how cogni-
tive changes are manifested according to gender in relation 
to HIV and AIDS,12 and these have yielded somewhat 
conflicting results. Some studies have reported no differ-
ences between the genders in relation to the effects of HIV 
on neurocognition,17 whereas other studies have reported 
a higher prevalence of NCI among HIV-positive women.2 
Previous studies carried out in Zambia18,19 have also revealed 
more HIV-related impairment in women relative to men. 
Seropositive females were reported to be significantly more 
impaired in neuropsychological tests compared to their male 
counterparts. Reports of both studies, however, are quick 
to point out that there is need for larger and more compre-
hensive studies to verify possible differences between the 
genders in HIV-related NC impairment. Also, there is a 
need for such studies to include NC normative corrections 
to control for performance differences related to gender, 
age, and education within the general (HIV uninfected) 
population.
Given the huge toll that HIV has taken on the popula-
tions of the world, and especially in its CNS manifestations, 
it is important to make strides in understanding possible 
differences between the genders in NC outcomes. This will 
enable health care professionals to provide gender specific 
management and treatment for people infected with HIV 
and AIDS.
The aim of the current cross-sectional study was to 
address whether there were differences between the genders 
in cognitive ability in a large sample of antiretroviral therapy 
(ART)-treated HIV-seropositive (HIV+) men and women in 
urban Zambia. We used a comprehensive NC test battery that 
has normative standards which control for demographic influ-
ences that exist in normal HIV-seronegative (HIV−) Zambian 
adults. Results were considered in relation to potentially 
relevant disease and treatment factors. We hypothesized that 
the seropositive females would be more cognitively impaired 
than the seropositive males.
Method
Participants
Our HIV+ sample was drawn from six urban clinics in the 
Zambian capital city Lusaka: Chilenje, Chipata, Kabwata, 
Kalingalinga, Matero Main, and Matero Referral clinics. 
The clinics were chosen because they routinely provide 
HIV counseling and testing services as well as treatment. 
All these clinics are under the management of the Lusaka 
District Health Management Team in Zambia. ART had been 
prescribed free of charge in these public health care centers 
in Zambia since 2004.20
inclusion and exclusion criteria
inclusion
1. HIV status – All study participants were HIV+ and on 
ART. Information about HIV and treatment status was 
based on the participants’ medical files.
2. Education level – The eligible participants were required 
to have a minimum of 5 years of formal education. 
English is the primary language of instruction in the 
Zambian school system, and the testing was performed 
in English.
3. Age range – All the participants were required to be 
between 20 and 65 years of age (to conform to the age 
range of the HIV− controls who participated in the 
Zambian NC norming study).21
exclusion
1. History of neurological disorders – Individuals with a 
history of non-HIV-related neurological problems, such 
as epilepsy, closed head injury, and coma for any reason, 
were excluded from the study. This information was 
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obtained using a neurobehavioral Medical Screen Form, 
which assesses past medical and neurological histories.22
2. History of drug abuse – Individuals with a history of drug 
abuse were excluded from the study. This information was 
obtained using a structured Substance Use form.23,24
3. Physical disabilities – Individuals with obvious physical 
disabilities were excluded from the study to minimize 
on the possibility of test performance requiring motor 
dexterity being impaired due to the handicap.
The target sample size was 324 participants, but only 266 
HIV+ participants were included in the current study because 
of some key missing pieces of information (owing to cases 
of spoiled data on the computer versions of the Category 
and Wisconsin Card Sorting tests), thus 58 participants were 
excluded at the time of analysis. The proportion of males 
and females in our study was consistent with reports for 
the general HIV+ population in Zambia (ie, 40% males and 
60% females).6 All the participants were on ART, and the age 
range of the participants was from 21 to 65 years (M=40.67, 
standard deviation [SD] =8.74). Education range, in number 
of years of formal education attained, was between 5 and 
20 years (M=9.9, SD =2.24).
Procedure
The recruitment process was carried out with the assistance 
of nurses at each clinic who identified participants meeting 
the inclusion criteria. Once informed consent was obtained, 
the participants were referred to one of ten Neuropsychology 
Master of Science students from University of Zambia, who 
had received extensive training in interviewing, as well as 
administration and scoring of the NC tests. The testing process 
for each participant took approximately 2 hours 30 minutes.
The first part of the testing process involved obtaining 
the participants’ demographic characteristics, medical, and 
psychiatric information based on self-report. Medical details 
were confirmed by the patients’ medical record provided by 
the medical personnel. Administration of NC tests of the test 
battery was carried out in the same order for all participants, 
and they were compensated the Zambian Kwacha equivalent 
of US$8 for transport and refreshment allowance at the end 
of the testing process.
Measures
cognitive functioning
Cognitive functioning was measured using an NC test 
battery that measures cognition across the seven ability 
domains that have been identified as frequently affected 
in HIV-associated neurocognitive disorders:25 Executive 
Functioning (Stroop Color–Word Interference trial, Category 
Test errors, Wisconsin Card Sorting Test – 64 Total errors, 
and Color Trails 2); Working Memory/Attention (Paced 
Auditory Serial Addition Test – 50 (PASAT) and Wechsler 
Memory Scale-III Spatial Span Test); Speed of Information 
Processing (Wechsler Adult Intelligence Scale-III [WAIS-
III], Digit Symbol, WAIS-III Symbol Search, Trails A, 
Color Trails 1, Stroop Color Naming and Stroop Word 
Naming), Verbal fluency (Letter fluency, Animal fluency, 
and Action fluency); Learning (Hopkins Verbal Learning 
Test – Revised [HVLT-R] learning and Brief Visuospatial 
Learning Test – Revised [BVMT-R] learning); Delayed recall 
(HVLT-R delay and BVMT delay); and complex Motor 
Function (Grooved Pegboard [dominant and nondominant 
hands]). The test battery is appropriate for the current study 
because it measures the domains typically affected by HIV.26 
It is an international well-recognized NC assessment tool 
that has been translated into multiple languages around the 
world.10,14,18,24,27 The battery has been adapted and normed 
for the Zambian population.21
Test items such as those on the HVLT-R were adapted 
to make them more culturally appropriate for Zambia. For 
instance, all the precious stones in the learning trial of the 
test were changed to metals that are common in Zambia 
(copper, iron, lead, and zinc). In the recognition trial, steel 
and bronze were added.21,23
Disease characteristics
Participants were categorized according to whether their 
HIV viral loads were detectable or undetectable. Viral 
load was detected at 50 copies/mL. This information was 
obtained from the patients’ medical files and is considered 
here because previous studies have reported HIV viral load 
detectability as an induction of effective therapy.28,29
Information on duration of ART was obtained from the 
patients’ medical files.
CD4 count included nadir CD4 ranging from 1 cells/mm3 
to 727 cells/mm3, and current CD4 taken at the time of testing 
for this study ranging from 0 cells/mm3 to 2,287 cells/mm3.
AIDS status constituted participants with AIDS and 
those without AIDS; this information was obtained from 
the participants’ medical files. AIDS is diagnosed in Zambia 
when an HIV-infected individual has a CD4 count below 
200 cells/mm3 of blood, weakening the immune system and 
putting the individual at risk of illnesses and infections that 
are AIDS defined according to the World Health Organization 
(WHO) stages (WHO Stages 3 and 4 condition).30,31
Nutritional information such as body mass index (BMI) 
has been linked to NC functioning.26 In the current study, BMI 
categories were based on the WHO classification: BMI values 
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of ,18.50 are regarded as low, 18.50–24.99 is regarded as 
normal, $25 is overweight, and $30 is obese.32
Tuberculosis (TB) is a common comorbid factor in HIV 
in sub-Saharan Africa and is reported to have an effect on NC 
functioning.33 In the current study, TB status was obtained 
from the patients’ medical files.
ethical consideration
The study was approved by the University of Zambia Bio-
medical Research Ethics Committee. The research was also 
formally approved by the Lusaka District Health Manage-
ment Team, which oversees the clinics in Lusaka and the 
Ministry of Health.
Written informed consent was obtained from all research 
participants. Participants had the ability to take breaks or with-
draw from the study at any time with no penalty incurred. All 
the data that was recorded was anonymous. The participants 
were assigned an arbitrary code for analysis purposes.
Data management
The raw data that was obtained on the neuropsychological 
test battery was converted into demographically corrected 
T-scores based on data previously collected from 324 healthy 
Zambians. The 324 healthy sample comprised 157 (48.5%) 
males and 167 (51.5%) females, with an average age of 38.5 
(SD =12.80) years and an average education level of 11.0 
(SD =2.58) years. The norming process was similar to that 
used for the US normative data.21,23 The raw scores were 
corrected for the effects of age, education, sex, and urban/
rural background by first converting them to normally dis-
tributed scaled scores with a mean of 10 and SD of 3; the 
scaled scores were then converted to demographically cor-
rected T-scores with a mean of 50 and SD of 10. Detailed 
procedures and results of the norming study have been 
reported elsewhere.21
Global Deficit Scores were used as an alternative method 
to determine the NCI levels of the participants.34 Global 
Deficit Score is a mean of impairment ratings that uses 
demographically corrected T-scores on a five-point scale 
from normal to severely impaired. A deficit score of 0 means 
normal performance (T-score $40), whereas a deficit score 
of 1 means mild impairment (T-score =35–39), 2 means 
mild-to-moderate impairment (T-score =30–34), 3 means 
moderate impairment (T-score =25–29), 4 means moderate-
to-severe impairment (T-score =20–24), and 5 means severe 
impairment (T-score ,20). Participants were classified as 
impaired in an ability domain if they had an average deficit 
score $0.5 on that particular cognitive domain. This average 
is called the Domain Deficit Score (DDS). Participants were 
further classified as having global impairment if they had a 
total average deficit score $0.5 across all domains.34–36
The use of the “deficit score” approach reflects our focus 
on abilities that may have been affected by CNS injury or 
disease. It has been used in many previous studies of HIV-
associated neurocognitive disorders and, similar to clinical 
ratings of NC results (which does not allow for good/normal 
performances on some tests or domains obscure problematic 
results on others), purposely gives less weight to high test 
scores in the normal range.34
Data analysis
All the data in this study was analyzed using the Statistical 
Package for Social Sciences version 20 (IBM Corporation, 
Armonk, NY, USA). The statistical package was used to 
obtain the distribution of the participant’s demographics 
and disease characteristics. It was also used to compute 
independent t-tests comparing males versus females within 
the HIV+ sample and to generate Chi-square analyses for the 
HIV+ male and female disease characteristics. Analyses of 
covariance were computed to compare male and female NC 
functioning while controlling for disease characteristics.
Results
Demographics
The HIV+ male participants were older (M=42.37, SD =9.37) 
than the HIV+ female participants (M=39.5, SD =8.11; 
P=0.009) and had more years of education (M=10.47, 
SD =2.33) than the HIV+ female participants (M=9.67, 
SD =2.12; P=0.004). However, the effects of “normal” 
age, education, and sex on the NC test performances were 
controlled for by using demographically corrected standard 
scores (T-scores) generated with a previously collected 324 
HIV− normative sample.21
Disease characteristics based on sex
To determine disease characteristics based on gender, inde-
pendent t-tests were computed for the continuous variables, 
such as current CD4 count, nadir CD4 count, and duration on 
ART. Chi-square tests were carried out for the dichotomous 
disease characteristics such as viral load detected/undetected, 
AIDS status, BMI, and TB status.
Current CD4 counts were statistically different between the 
males (mean =396.78, SD =235.52) and females (mean =539.02, 
SD =230.71) P#0.001. Nadir CD4 counts were not statistically 
different between the males (mean =180.87, SD =136.92) and 
females (mean =215.93, SD =156.07), P=0.108.
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Duration on ART was not statistically different between the 
males (mean =52.96, SD =32.75) and females (mean =55.95, 
SD =31.42), P=0.506.
Table 1 outlines the disease and immune characteristics 
of the HIV+ participants stratified by gender.
Chi-square tests for independence with Yates continuity 
correction (Table 1) and independent t-test analyses revealed 
statistically significant differences with regard to gender and 
disease characteristics for viral load, AIDS status, TB status, 
BMI, and current CD4. Males were more likely to have 
AIDS, detectable viral loads, had more current immunosup-
pression (lower CD4 cell counts), and were more likely to 
have TB coinfection, whereas females were more likely to 
be overweight. Thus, the males were sicker and had a worse 
immunological status, both at the inception of ART and also 
at the time of testing for the current study when compared 
to the female participants. We further sought to determine 
how these aforementioned disease characteristics may have 
impacted on NC functioning in our seropositive male and 
female samples.
Overall Nc functioning
Using T-scores, we examined whether there were any gender-
related cognitive differences in our seropositive participants 
on overall NC functioning. Results obtained for the seven 
cognitive domains and the global mean score are presented 
in Table 2.
Results in Table 2 indicated that there were no statistically 
significant differences between the HIV+ males and females 
on the overall and domain T-scores in neuropsychological 
test performance. Similar results were also obtained when 
the HIV+ males and females were compared using DDS 
(data not shown).
Disease characteristics and Nc 
functioning of the hiV+ males and 
females
One-way analyses of covariance to compare the performance 
of males and females on NC functioning were carried out 
while controlling for differences in disease characteristics. 
The grouping variable was gender. The intention was to look 
at differences between males and females while controlling 
for covariates, these being disease characteristics associated 
with HIV infection. Dependent variables were NC mean 
T-scores and DDS across the seven domains. Covariates were 
disease characteristics: categorical variables (detectable/
undetectable viral load, AIDS, and TB status) and continu-
ous variables (nadir CD4, current CD4, duration on ART, 
and BMI).
Statistically significant results were observed on the fol-
lowing domains.
Mean T-scores
Learning mean T-score: There was a statistically significant 
effect of gender F(1,117) =7.42, P=0.007, partial η2=0.06, 
with an adjusted mean T-score for males of 46.62 (standard 
error [SE] =0.96) and females of 43.02 (SE =0.84). There 
were no statistically significant effects for the covariates, 
Table 1 hiV+ male and female participants’ disease and immune 
characteristics
Disease characteristics Males (%) Females (%) P-value
Viral load 0.044
Detected 25.5 15.2
Undetected 74.5 84.8
aiDs status 0.007
aiDs 60.71 42.96
Non-aiDs 39.29 57.04
BMi ,0.001
Normal 76.6 58.5
Underweight 15.6 3.4
Overweight 5.6 27.1
Obese 2.2 11.0
TB status 0.015
With TB 45.92 24.83
Without TB 54.08 75.83
Abbreviations: HIV, human immunodeficiency virus; AIDS, acquired immune 
deficiency syndrome; BMI, body mass index; TB, tuberculosis.
Table 2 T-scores-based results comparing hiV+ males and hiV+ females on ability domains
Ability domains Males mean (SD) Females mean (SD) t P-value Cohen’s d
executive functioning mean 46.49 (6.45) 46.16 (6.29) 0.41 0.68 0.05
Working memory mean 43.57 (8.20) 44.97 (8.49) −1.33 0.19 −0.16
speed of information processing mean 46.07 (7.09) 45.89 (7.39) 0.19 0.84 0.02
Verbal fluency mean 46.07 (7.06) 46.66 (7.91) −0.55 0.58 −0.07
learning mean 44.58 (8.51) 43.97 (7.92) 0.59 0.55 0.07
Delayed recall mean 45.57 (8.38) 44.63 (7.88) 0.93 0.35 0.12
Motor functioning mean 52.46 (10.24) 51.61 (10.81) 0.64 0.52 0.08
global mean 46.36 (5.53) 46.22 (5.77) 0.19 0.85 0.02
Abbreviations: HIV, human immunodeficiency virus; SD, standard deviation.
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detectable/undetectable viral load, AIDS and TB status, nadir 
CD4, current CD4, duration on ART, and BMI.
Delayed recall mean T-score: There was a statistically 
significant effect of gender, F(1,117) =8.78, P=0.004, 
partial η2=0.070, with an adjusted mean T-score for males of 
47.99 (SE =1.05) relative to 43.68 (SE =0.92) in the female 
group. A statistically significant effect was also obtained for 
the covariate TB, F(1,117) =3.99, P=0.048, partial η2=0.033, 
indicating more TB in the male group. There were no statisti-
cally significant effects of the other covariates, detectable/
undetectable viral load, AIDS status, nadir CD4, current CD4, 
duration on ART, and BMI on recall mean T-score.
Motor mean T-score: There was no statistically significant 
effect of gender, F(1,117) =0.394, P=0.531, partial η2=0.003. 
Statistically significant effects were found for the covari-
ates current CD4 count, F(1,117) =9.27, P=0.003, partial 
η2=0.073, and nadir CD4 count, F(1,117) =6.27, P=0.011, 
partial η2=0.054, with an adjusted mean T-score for males 
of 53.65 (SE =1.45) and females of 52.39 (SE =1.26). The 
other covariates, detectable/undetectable viral load, AIDS 
status, TB status duration on ART, and BMI, did not have a 
statistically significant effect on the motor mean T-score.
Speed of information processing T-score: There was no 
statistically significant effect of gender, F(1,117) =2.24, 
P=0.123, partial η2=0.020. A statistically significant 
effect was found for the covariate current CD4 count, 
F(1,117) =4.93, P=0.028, partial η2=0.040, with an adjusted 
mean T-score for males of 48.09 (SE =1.02) and females of 
45.89 (SE =0.894). There were no statistically significant 
effects of the other covariates: undetectable/detectable viral 
load, AIDS status, TB status, nadir CD4, duration on ART, 
and BMI on speed of information processing T-score.
Global mean T-score: There was no statistically significant 
effect of gender F(1,117) =2.93, P=0.089, partial η2=0.024. 
A statistically significant effect was found for current CD4 
count, F(1,117) =5.91, P=0.012, partial η2=0.048, with an 
adjusted mean T-score for males: 48.14 (SE =0.76) and 
females: 46.35 (SE =0.66). There were no statistically sig-
nificant effects of the other covariates such as undetectable/
detectable viral load, AIDS status, TB status, nadir CD4, 
duration on ART, and BMI on the global mean T-score.
Domain deficit scores
Learn mean DDS: There was no statistically significant 
effect of gender F(1,117) =2.79, P=0.097, partial η2=0.023. 
A statistically significant effect was found for the covariate 
duration on ART, F(1,117) =6.09, P=0.015, partial η=0.049, 
with an adjusted mean T-score for males: 0.333 (SE =0.095) 
and females: 0.552 (SE =0.083). The other covariates, 
detectable/undetectable viral load, AIDS status, TB status, 
nadir CD4, current CD4, and BMI, did not have statistically 
significant effects on learn mean DDS.
Delayed recall mean DDS: There was a statistically sig-
nificant effect for gender, F(1,117) =9.70, P=0.002, partial 
η2=0.077, with an adjusted mean T-score for males of 0.236 
(SE =0.094) and for females of 0.641 (SE =0.082). There 
were no statistically significant effects for the covariates 
such as detectable/undetectable viral load, AIDS and TB 
status, nadir CD4, current CD4, duration on ART, and BMI 
on recall mean DDS.
Discussion
Nc functioning of hiV+ males compared 
to hiV+ females
Unadjusted comparisons of the HIV+ males and females on both 
the T-scores and DDS did not yield any significant differences 
between the two groups. The results obtained in this regard are 
in agreement with some previous studies that have shown no 
overall differences between HIV+ males and females,17,37,38 but 
were at odds with those that were previously reported in Zambia, 
suggesting significant gender differences in NC functioning 
owing to HIV infection. Possible reasons for this disparity could 
be that previous studies had smaller sample sizes, did not utilize 
Zambian norms, and/or did not employ a comprehensive test 
battery.19,18 Furthermore, the prior studies did not correct for 
possible differences in disease characteristics.
Disease characteristics and gender in 
relation to Nc functioning
Our analyses revealed that males were significantly sicker 
than the females. That is to say, the males had a more 
impaired immune system both at the time of the current study 
and when they were initially introduced to ART, were more 
likely to have AIDS and to have detectable virus on ART, 
and more likely to have coinfection with TB. This revelation 
could possibly be as a result of women actually seeking treat-
ment at an earlier time than men, either due to opportunistic 
infections or because they are more aware of signs of sickness 
than the men. This possibility is consistent with results of a 
study that showed that males are less likely to seek medical 
treatment in the earlier clinical stages of HIV than females.39 
This trend has been linked to cultural and social issues to 
do with masculinity and power that demand physical and 
emotional strength from the male population, thus making 
them less likely to seek treatment early as a way of avoiding 
feelings of vulnerability and loss of power.40
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gender and hiV neurocognition
Nevertheless, when we explored the cognitive function-
ing of HIV+ males and HIV+ females while controlling for 
disease characteristics, the females were more impaired 
compared to their male counterparts in the cognitive domains 
of learning and recall using the T-scores corrected for disease 
characteristics and the DDS. The females further performed 
worse than the males on motor, speed of information process-
ing, and global mean T-scores.
It is worth mentioning that in spite of the males having 
more severe illness than their female counterparts, they still 
managed to perform relatively better on NC tests. Reasons for 
poorer relative NC outcomes in females might be attributed 
to either genetic or social factors or a combination of these 
factors. Some scholars41 postulate that seropositive females 
could be at greater risk of developing neuropsychologi-
cal impairments compared to seropositive males. There is 
thus a great need to better understand what factors could 
be accounting for the gender differences we found in both 
disease severity and its associated NC outcomes.
Conclusion and recommendation
The findings obtained from this study raise an important need 
to investigate further the extent to which the HIV+ female 
population could be more negatively affected by HIV infec-
tion on cognitive functioning relative to HIV+ males.
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